ROQ Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £70,136.27
Insider Selling (Last 12 Months): GBX 0

Roquefort Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Roquefort Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roquefort Therapeutics Share Price & Price History

Current Price: GBX 8
Price Change: Price Increase of +0.5 (6.67%)
As of 09/26/2022 04:32 PM ET

This chart shows the closing price history over time for ROQ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Roquefort Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/26/2022Dr Darrin DisleyInsiderBuy515,913GBX 8£41,273.04
7/4/2022Stephen Paul WestInsiderBuy210,000GBX 9£18,900
6/30/2022Stephen Paul WestInsiderBuy55,147GBX 9£4,963.23
1/19/2022Stephen Paul WestInsiderBuy50,000GBX 10£5,000
See Full Table

SEC Filings (Institutional Ownership Changes) for Roquefort Therapeutics (LON:ROQ)

Roquefort Therapeutics logo
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Read More on Roquefort Therapeutics

Today's Range

Now: GBX 8
Low: 7.51
High: 8

50 Day Range

Low: 7.27
High: 8.88

52 Week Range

Now: GBX 8
Low: 7.25
High: 13.63


526,727 shs

Average Volume

384,212 shs

Market Capitalization

£5.75 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Roquefort Therapeutics?

Roquefort Therapeutics' top insider investors include:
  1. Dr Darrin Disley (Insider)
  2. Stephen Paul West (Insider)
Learn More about top insider investors at Roquefort Therapeutics.